Heartbeam (BEAT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Jun, 2026Executive summary
The annual meeting is scheduled for July 31, 2026, to be held virtually, with shareholders able to vote online or by proxy on key proposals.
Shareholders of record as of June 5, 2026, are entitled to vote on the election of directors, auditor appointment, and an amendment to the equity plan.
The Board recommends voting in favor of all proposals, including director elections, auditor ratification, and the equity plan amendment.
Voting matters and shareholder proposals
Nine directors are nominated for election to serve until the 2027 annual meeting.
Proposal to ratify CBIZ CPAs P.C. as the independent registered public accounting firm for 2026.
Proposal to amend the 2022 Equity Incentive Plan to increase authorized shares by 3,000,000.
Shareholders may submit proposals for the 2027 annual meeting by February 18, 2027.
Board of directors and corporate governance
The Board consists of nine members with diverse backgrounds in healthcare, technology, and investment.
Seven directors are deemed independent under NASDAQ rules.
The Board has established audit, compensation, nominating and governance, and commercialization committees.
The roles of CEO and Chairman are separated to enhance oversight and governance.
The Board and committees regularly assess risk, compliance, and succession planning.
Latest events from Heartbeam
- Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing18 Jun 2026 - FDA-cleared at-home 12-lead ECG platform targets $40B market with scalable, AI-driven growth.BEAT
Investor presentation5 Jun 2026 - Net loss narrowed, cash burn fell, and $11.5M funding supports clinical and commercial growth.BEAT
Q1 202613 May 2026 - FDA-cleared 12-lead ECG platform targets $40B market with at-home cardiac monitoring innovation.BEAT
Investor presentation13 May 2026 - FDA-cleared ECG tech launches with strong demand, narrowing losses, and AI-driven growth ahead.BEAT
Q4 20253 May 2026 - At-home 12-lead ECG platform launches with subscription model and AI-driven expansion.BEAT
Oppenheimer 36th Annual Healthcare MedTech & Services Conference16 Mar 2026 - FDA-cleared portable ECG system targets $100M capital raise in expanding cardiac monitoring market.BEAT
Registration Filing13 Mar 2026 - FDA-cleared, cable-free 12-lead ECG platform targets $40B+ cardiac monitoring market.BEAT
Investor presentation12 Mar 2026 - Shelf registration for $100M supports launch of FDA-cleared portable 12-lead ECG system.BEAT
Registration Filing9 Feb 2026